Nurix Therapeutics
NRIX
173 hedge funds and large institutions have $783M invested in Nurix Therapeutics in 2025 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 49 increasing their positions, 60 reducing their positions, and 24 closing their positions.
981% more call options, than puts
Call options by funds: $1.12M | Put options by funds: $104K
42% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 24
6% more funds holding
Funds holding: 163 → 173 (+10)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.96% less ownership
Funds ownership: 115.85% → 110.89% (-5%)
18% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 60
22% less capital invested
Capital invested by funds: $1.01B → $783M (-$223M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$15.3M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$11.1M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$10.3M |
| 4 |
Millennium Management
New York
|
+$6.19M |
| 5 |
AG
Algert Global
San Francisco,
California
|
+$4.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$20.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.1M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$13.3M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$12.7M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$12.6M |
NRIX Hedge Fund Activity: Q3 2025 in Review
173 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q3 2025, worth a combined $783M — down 22% from $1.01B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new NRIX positions and 24 closed out — a net gain of 10 holders — while 49 added to existing stakes and 60 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $15.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $20.1M.
- 173 institutional investors held Nurix Therapeutics (NRIX) as of Q3 2025, up from 163 in Q2 2025.
- Funds reported $783M of Nurix Therapeutics stock for Q3 2025, down 22% quarter-over-quarter.
- 34 funds opened new Nurix Therapeutics positions in Q3 2025 and 24 closed out, a net change of +10 holders.
- The largest Nurix Therapeutics buyer in Q3 2025 was Vestal Point Capital, an estimated $15.3M added.
- The largest Nurix Therapeutics seller in Q3 2025 was T. Rowe Price Associates, an estimated $20.1M sold.
Based on aggregated 13F filings for Q3 2025.